Cassava Sciences shares rise 10.69% after-hours as CEO buys 150,000 shares.

Cassava Sciences surged 10.69% in after-hours trading following a filing revealing CEO Richard Barry purchased 150,000 shares in November. The insider buying signaled management confidence in the company’s clinical-stage Alzheimer’s therapies, including its lead candidate Simufilam, which is in Phase III trials. While other news items referenced broader market trends or unrelated stocks, the CEO’s purchase directly correlated with the stock’s upward move, reflecting optimism about the firm’s pipeline and potential regulatory progress.